Skip to main content
Top

Open Access 25-08-2023 | Cardiac Resynchronization Therapy | Original Paper

Topological data analysis to identify cardiac resynchronization therapy patients exhibiting benefit from an implantable cardioverter-defibrillator

Authors: Boglárka Veres, Walter Richard Schwertner, Márton Tokodi, Ádám Szijártó, Attila Kovács, Eperke Dóra Merkel, Anett Behon, Luca Kuthi, Richárd Masszi, László Gellér, Endre Zima, Levente Molnár, István Osztheimer, Dávid Becker, Annamária Kosztin, Béla Merkely

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Background

Current guidelines recommend considering multiple factors while deciding between cardiac resynchronization therapy with a defibrillator (CRT-D) or a pacemaker (CRT-P). Nevertheless, it is still challenging to pinpoint those candidates who will benefit from choosing a CRT-D device in terms of survival.

Objective

We aimed to use topological data analysis (TDA) to identify phenogroups of CRT patients in whom CRT-D is associated with better survival than CRT-P.

Methods

We included 2603 patients who underwent CRT-D (54%) or CRT-P (46%) implantation at Semmelweis University between 2000 and 2018. The primary endpoint was all-cause mortality. We applied TDA to create a patient similarity network using 25 clinical features. Then, we identified multiple phenogroups in the generated network and compared the groups’ clinical characteristics and survival.

Results

Five- and 10-year mortality were 43 (40–46)% and 71 (67–74)% in patients with CRT-D and 48 (45–50)% and 71 (68–74)% in those with CRT-P, respectively. TDA created a circular network in which we could delineate five phenogroups showing distinct patterns of clinical characteristics and outcomes. Three phenogroups (1, 2, and 3) included almost exclusively patients with non-ischemic etiology, whereas the other two phenogroups (4 and 5) predominantly comprised ischemic patients. Interestingly, only in phenogroups 2 and 5 were CRT-D associated with better survival than CRT-P (adjusted hazard ratio 0.61 [0.47–0.80], p < 0.001 and adjusted hazard ratio 0.84 [0.71–0.99], p = 0.033, respectively).

Conclusions

By simultaneously evaluating various clinical features, TDA may identify patients with either ischemic or non-ischemic etiology who will most likely benefit from the implantation of a CRT-D instead of a CRT-P.

Graphical abstract

Topological data analysis to identify phenogroups of CRT patients in whom CRT-D is associated with better survival than CRT-P. AF atrial fibrillation, CRT cardiac resynchronization therapy, CRT-D cardiac resynchronization therapy defibrillator, CRT-P cardiac resynchronization therapy pacemaker, DM diabetes mellitus, HTN hypertension, LBBB left bundle branch block, LVEF left ventricular ejection fraction, MDS multidimensional scaling, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association
Appendix
Available only for authorised users
Literature
1.
go back to reference Moss AJ et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329–1338CrossRefPubMed Moss AJ et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329–1338CrossRefPubMed
2.
go back to reference Bristow MR et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140–2150CrossRefPubMed Bristow MR et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140–2150CrossRefPubMed
3.
go back to reference Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549CrossRefPubMed Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549CrossRefPubMed
4.
go back to reference Glikson M et al (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 42(35):3427–3520CrossRefPubMed Glikson M et al (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 42(35):3427–3520CrossRefPubMed
5.
go back to reference Barra S et al (2017) Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate. J Am Coll Cardiol 69(13):1669–1678CrossRefPubMed Barra S et al (2017) Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate. J Am Coll Cardiol 69(13):1669–1678CrossRefPubMed
6.
go back to reference Leyva F et al (2018) Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace 20(11):1804–1812CrossRefPubMedPubMedCentral Leyva F et al (2018) Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace 20(11):1804–1812CrossRefPubMedPubMedCentral
7.
go back to reference Casaclang-Verzosa G et al (2019) Network tomography for understanding phenotypic presentations in aortic stenosis. JACC Cardiovasc Imaging 12(2):236–248CrossRefPubMed Casaclang-Verzosa G et al (2019) Network tomography for understanding phenotypic presentations in aortic stenosis. JACC Cardiovasc Imaging 12(2):236–248CrossRefPubMed
8.
go back to reference Tokodi M et al (2020) Interpatient similarities in cardiac function: a platform for personalized cardiovascular medicine. JACC Cardiovasc Imaging 13(5):1119–1132CrossRefPubMedPubMedCentral Tokodi M et al (2020) Interpatient similarities in cardiac function: a platform for personalized cardiovascular medicine. JACC Cardiovasc Imaging 13(5):1119–1132CrossRefPubMedPubMedCentral
9.
go back to reference Hwang D et al (2021) Topological data analysis of coronary plaques demonstrates the natural history of coronary atherosclerosis. JACC Cardiovasc Imaging 14(7):1410–1421CrossRefPubMed Hwang D et al (2021) Topological data analysis of coronary plaques demonstrates the natural history of coronary atherosclerosis. JACC Cardiovasc Imaging 14(7):1410–1421CrossRefPubMed
11.
go back to reference Blondel VD et al (2008) Fast unfolding of communities in large networks. J Stat Mech 2008(10):P10008CrossRef Blondel VD et al (2008) Fast unfolding of communities in large networks. J Stat Mech 2008(10):P10008CrossRef
12.
go back to reference Glikson M et al (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J 42(35):3427–3520CrossRefPubMed Glikson M et al (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J 42(35):3427–3520CrossRefPubMed
13.
go back to reference Doran B et al (2021) The addition of a defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC 9(6):439–449PubMed Doran B et al (2021) The addition of a defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC 9(6):439–449PubMed
14.
go back to reference Leyva F et al (2012) Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 60(17):1659–1667CrossRefPubMed Leyva F et al (2012) Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 60(17):1659–1667CrossRefPubMed
15.
go back to reference Barra S et al (2019) Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. Eur Heart J 41(21):1976–1986CrossRef Barra S et al (2019) Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. Eur Heart J 41(21):1976–1986CrossRef
16.
18.
go back to reference Hadwiger M et al (2022) Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. Eur Heart J 43(27):2591–2599CrossRefPubMedPubMedCentral Hadwiger M et al (2022) Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. Eur Heart J 43(27):2591–2599CrossRefPubMedPubMedCentral
19.
go back to reference Linde C (2022) CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study. Eur Heart J 43(27):2600–2602CrossRefPubMed Linde C (2022) CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study. Eur Heart J 43(27):2600–2602CrossRefPubMed
20.
go back to reference Kutyifa V et al (2014) Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail 16(12):1323–1330CrossRefPubMed Kutyifa V et al (2014) Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail 16(12):1323–1330CrossRefPubMed
21.
go back to reference Moss AJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877–883CrossRefPubMed Moss AJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877–883CrossRefPubMed
22.
go back to reference Bardy GH et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3):225–237CrossRefPubMed Bardy GH et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3):225–237CrossRefPubMed
23.
go back to reference Witt CT et al (2016) Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace 18(3):413–419CrossRefPubMed Witt CT et al (2016) Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace 18(3):413–419CrossRefPubMed
24.
go back to reference Køber L et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230CrossRefPubMed Køber L et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230CrossRefPubMed
25.
go back to reference Cikes M et al (2019) Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail 21(1):74–85CrossRefPubMed Cikes M et al (2019) Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail 21(1):74–85CrossRefPubMed
Metadata
Title
Topological data analysis to identify cardiac resynchronization therapy patients exhibiting benefit from an implantable cardioverter-defibrillator
Authors
Boglárka Veres
Walter Richard Schwertner
Márton Tokodi
Ádám Szijártó
Attila Kovács
Eperke Dóra Merkel
Anett Behon
Luca Kuthi
Richárd Masszi
László Gellér
Endre Zima
Levente Molnár
István Osztheimer
Dávid Becker
Annamária Kosztin
Béla Merkely
Publication date
25-08-2023